Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):383–387. doi: 10.1038/bjc.1993.70

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

P R Taylor 1, G H Jackson 1, A L Lennard 1, H Lucraft 1, S J Proctor 1
PMCID: PMC1968195  PMID: 8431371

Abstract

This study aimed to assess the safety and efficacy of using high dose melphalan and etoposide followed by autologous, non-cryopreserved marrow rescue in advanced Hodgkin's disease (HD). Seventeen patients with poor risk Hodgkin's disease from a single centre underwent autologous bone marrow transplant (ABMT) using high dose melphalan and etopside conditioning. Two patients had primary progressive resistant disease (PD), two were in fourth relapse, six in second or third complete remission (CR), one patient had good partial response (GPR) (> 75% reduction in initial bulk) to primary therapy and six were in first complete remission. The patients transplanted in first CR all has a Scotland and Newcastle Lymphoma Group (SNLG) Prognostic Index (Proctor et al., 1991) which indicated they were in a poor risk prognostic group. Melphalan and etoposide both have a short half life enabling ABMT to be accomplished using unmanipulated marrow stored at 4 degrees C. The marrow was returned to the patient within 56 h of harvest. Complete haematological reconstitution occurred in 16/17 patients, the rate of engraftment reflecting the amount of previous chemotherapy. One patient died of progressive Hodgkin's disease before full engraftment could occur. In patients autografted in first remission, the median number of days with neutropenia (< 0.5 x 10(9) l-1 neutrophils) was 19 (range 9-33) and, in those in subsequent remission, 27 days (range 18-36). The median number of days to 50 x 10(9) l-1 platelets in the same groups were 29 (21-80) and 50 (41-74) respectively. The number of days in hospital post transplant in both groups was similar; median 22 (15-27) and 23 (17-37) respectively. There were no procedural deaths and none of the patients transplanted in first, second or third CR have relapsed (median follow up 21 months). The two patients transplanted with progressive disease showed only temporary responses. The two patients transplanted in fourth relapse went into CR; one is still alive and in CR 15 months post transplant, but the other relapsed 18 months post transplant. This form of intensification therapy with marrow rescue has been shown to be effective and of low toxicity and now forms part of a randomised controlled trial in poor risk Hodgkin's patients as identified by the SNLG index (Proctor et al., 1992).

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage J. O., Bierman P. J., Vose J. M., Anderson J. R., Weisenburger D. D., Kessinger A., Reed E. C., Vaughan W. P., Coccia P. F., Purtilo D. T. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med. 1991 Dec;91(6):605–611. doi: 10.1016/0002-9343(91)90213-h. [DOI] [PubMed] [Google Scholar]
  2. Blume K. G., Forman S. J., O'Donnell M. R., Doroshow J. H., Krance R. A., Nademanee A. P., Snyder D. S., Schmidt G. M., Fahey J. L., Metter G. E. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood. 1987 Apr;69(4):1015–1020. [PubMed] [Google Scholar]
  3. Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739–746. doi: 10.7326/0003-4819-104-6-739. [DOI] [PubMed] [Google Scholar]
  4. Carey P. J., Proctor S. J., Taylor P., Hamilton P. J. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood. 1991 Apr 1;77(7):1593–1598. [PubMed] [Google Scholar]
  5. Gribben J. G., Linch D. C., Singer C. R., McMillan A. K., Jarrett M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989 Jan;73(1):340–344. [PubMed] [Google Scholar]
  6. Jagannath S., Armitage J. O., Dicke K. A., Tucker S. L., Velasquez W. S., Smith K., Vaughan W. P., Kessinger A., Horwitz L. J., Hagemeister F. B. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb;7(2):179–185. doi: 10.1200/JCO.1989.7.2.179. [DOI] [PubMed] [Google Scholar]
  7. Jagannath S., Dicke K. A., Armitage J. O., Cabanillas F. F., Horwitz L. J., Vellekoop L., Zander A. R., Spitzer G. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986 Feb;104(2):163–168. doi: 10.7326/0003-4819-104-2-163. [DOI] [PubMed] [Google Scholar]
  8. Klimo P., Connors J. M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. Semin Hematol. 1988 Apr;25(2 Suppl 2):34–40. [PubMed] [Google Scholar]
  9. Lennard A. L., Carey P. J., Jackson G. H., Proctor S. J. An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol. 1990;26(4):301–305. doi: 10.1007/BF02897235. [DOI] [PubMed] [Google Scholar]
  10. Proctor S. J., Hamilton P. J., Taylor P., Carey P., Hargrave S., Evans R. G., Summerfield G., Finney R., Saunders P., Goff D. A comparative study of combination chemotherapy versus marrow transplant in first remission in adult acute lymphoblastic leukaemia. Br J Haematol. 1988 May;69(1):35–39. doi: 10.1111/j.1365-2141.1988.tb07599.x. [DOI] [PubMed] [Google Scholar]
  11. Proctor S. J., Taylor P., Donnan P., Boys R., Lennard A., Prescott R. J. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer. 1991;27(5):624–629. doi: 10.1016/0277-5379(91)90231-2. [DOI] [PubMed] [Google Scholar]
  12. Proctor S. J., Taylor P., Mackie M. J., Donnan P., Boys R., Lennard A., Prescott R. J. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma. 1992;7 (Suppl):17–20. doi: 10.3109/10428199209061558. [DOI] [PubMed] [Google Scholar]
  13. Proctor S. J., Taylor P., Thompson R. B., Finney R., Reid M. M., Hamilton P. J., Saunders P., Fail B., Dickinson A., Paul B. Acute lymphoblastic leukaemia in adults in the northern region of England--a study of 75 cases. Q J Med. 1985 Nov;57(223):761–774. [PubMed] [Google Scholar]
  14. Reece D. E., Barnett M. J., Connors J. M., Fairey R. N., Fay J. W., Greer J. P., Herzig G. P., Herzig R. H., Klingemann H. G., LeMaistre C. F. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991 Oct;9(10):1871–1879. doi: 10.1200/JCO.1991.9.10.1871. [DOI] [PubMed] [Google Scholar]
  15. Russell J. A., Selby P. J., Ruether B. A., Mbidde E. K., Ashley S., Zulian G., Berry J., Houwen B., Jones A. R., Poon M. C. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant. 1989 Jul;4(4):425–429. [PubMed] [Google Scholar]
  16. Wolff S. N., Fer M. F., McKay C. M., Hande K. R., Hainsworth J. D., Greco F. A. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol. 1983 Nov;1(11):701–705. doi: 10.1200/JCO.1983.1.11.701. [DOI] [PubMed] [Google Scholar]
  17. Zulian G. B., Selby P., Milan S., Nandi A., Gore M., Forgeson G., Perren T. J., McElwain T. J. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer. 1989 Apr;59(4):631–635. doi: 10.1038/bjc.1989.128. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES